Explain this page
Arphra AIPlain-English read on Avis Budget Group, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for CAR.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.44% | +2.11% | +6.86% | +87.82% | +34.36% | +40.15% | +60.19% | +2.29% | +110.37% | +452.17% | +8847.35% |
Aftermarket
LiveLast trade
$179.84
6 sh
Bid
$180.13
19 sh
Ask
$180.59
80 sh
Spread
$0.460
Sector & industry today
LiveSectors
- Technology+1.97%
- Healthcare+1.64%
- Energy+0.88%
- Industrials+0.66%
- Communication Services+0.35%
- Basic Materials+0.13%
- Utilities+0.10%
- Real Estate-0.19%
- Consumer Cyclical-0.73%
- Consumer Defensive-0.82%
- Financial Services-1.06%
Top industries (issuer's industry highlighted)
- Rental & Leasing Services+0.90%
- Broadcasting+6.61%
- Medical - Equipment & Services+4.40%
- Communication Equipment-3.75%
- Software - Infrastructure+3.40%
- Coal+2.71%
- Oil & Gas Drilling+2.59%
- Real Estate - Development+2.53%
- Medical - Healthcare Information Services-2.36%
- Oil & Gas Energy+2.20%
- Biotechnology+2.14%
- Medical - Healthcare Plans+2.14%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $124.83 (-30.59%)
Total assets
$32.19B
Total debt
$31.17B
Cash & equiv
$519M
Operating CF
$3.3B
Free cash flow
-$11.98B
Buybacks
-$7M
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphomaaccessnewswire.com·Jun 04, 2026
- Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsglobenewswire.com·May 12, 2026
- Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsglobenewswire.com·May 12, 2026
- OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studiesglobenewswire.com·May 12, 2026
- OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studiesglobenewswire.com·May 12, 2026
- Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapyprnewswire.com·May 11, 2026
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseasesglobenewswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.53B | -$283M | $-8.02 |
| Q4 Dec 2025 | $2.66B | -$747M | $-21.22 |
| Q3 Sep 2025 | $3.52B | $359M | $10.11 |
| Q2 Jun 2025 | $3.04B | $4M | $0.11 |
| Q1 Mar 2025 | $2.43B | -$505M | $-14.35 |
| Q4 Dec 2024 | $2.71B | -$1.96B | $-55.66 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $11.65B | $1.28B | -$889M | $-25.26 | -7.63% |
| FY 2024 | $11.79B | $1.5B | -$1.82B | $-51.23 | -15.45% |
| FY 2023 | $12.01B | $2.35B | $1.63B | $42.06 | +13.59% |
| FY 2022 | $11.99B | $3.28B | $2.76B | $57.11 | +23.04% |
| FY 2021 | $9.31B | $2.09B | $1.29B | $19.44 | +13.80% |